Novartis Ag (NVS) Current Taxes (2009 - 2026)
Novartis Ag (NVS) posted Current Taxes of $2.3 billion for Q2 2026, up 17.42% sequentially from $2.0 billion in Q4 2025, and down 18.19% YoY from $2.8 billion in Q2 2025.
Novartis Ag (NVS) Current Taxes (2009 - 2026) Analysis & Trends
Novartis Ag has reported Current Taxes for 18 years, with the latest figure at $2.3 billion in Q2 2026.
- Quarterly Current Taxes fell 18.19% year-over-year to $2.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.3 billion (down 18.19% YoY) and the FY2025 annual result came in at $2.0 billion, up 23.14% from the prior year.
- Current Taxes rose to $2.3 billion in Q2 2026 per NVS's latest filing, from $2.0 billion in the prior quarter.
- Over five years, Current Taxes peaked at $2.8 billion in Q2 2025 and troughed at -$301.0 million in Q1 2024.
- A 5-year average of $1.8 billion and a median of $2.0 billion in 2025 frame the typical range for Current Taxes.
- The sharpest annual moves came in 2024 and 2025: Current Taxes decreased 27.61% in 2024, then soared 47.26% in 2025.
- Over 5 years, Current Taxes stood at $2.5 billion in 2022, then declined by 25.27% to $1.9 billion in 2023, then fell by 15.53% to $1.6 billion in 2024, then advanced by 23.14% to $2.0 billion in 2025, then gained by 17.42% to $2.3 billion in 2026.
- According to Business Quant data, Current Taxes over the past three periods registered $2.3 billion, $2.0 billion, and $2.8 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.85 Bn | 633.09 Bn | 17.26 Bn | 1.05 Bn |
| 2 | AbbVie | 471.53 Bn | 464.96 Bn | 12.70 Bn | - |
| 3 | Merck | 380.02 Bn | 372.88 Bn | 12.21 Bn | 4.22 Bn |
| 4 | Novartis Ag | 303.58 Bn | 295.89 Bn | 11.24 Bn | 2.31 Bn |
| 5 | Astrazeneca | 258.47 Bn | 253.57 Bn | 12.86 Bn | 1.47 Bn |
| 6 | Amgen | 237.24 Bn | 223.25 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 183.09 Bn | 179.91 Bn | 6.22 Bn | - |
| 8 | Pfizer | 161.82 Bn | 150.12 Bn | 10.94 Bn | 653.00 Mn |
| 9 | Gsk | 105.93 Bn | 101.77 Bn | 8.24 Bn | -703.04 Mn |
| 10 | Sanofi | 55.25 Bn | 47.87 Bn | 10.79 Bn | 1.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.31 Bn |
| Dec 31, 2025 | 1.97 Bn |
| Jun 30, 2025 | 2.83 Bn |
| Dec 31, 2024 | 1.60 Bn |
| Jun 30, 2024 | 1.92 Bn |
| Mar 31, 2024 | -301.00 Mn |
| Dec 31, 2023 | 1.89 Bn |
| Sep 30, 2023 | 203.00 Mn |
| Jun 30, 2023 | 2.65 Bn |
| Dec 31, 2022 | 2.53 Bn |
| Jun 30, 2022 | 2.45 Bn |
| Dec 31, 2021 | 2.42 Bn |
| Jun 30, 2021 | 2.37 Bn |
| Dec 31, 2020 | 2.46 Bn |
| Jun 30, 2020 | 2.57 Bn |
| Dec 31, 2019 | 2.19 Bn |
| Jun 30, 2019 | 2.20 Bn |
| Mar 31, 2019 | 160.00 Mn |
| Dec 31, 2018 | 2.04 Bn |
| Jun 30, 2018 | 1.70 Bn |